U.S. Dollar Slides Toward Biggest Annual Loss Since 2017 as 2026 Risks Loom 
Asian Markets End Year on AI Optimism as Precious Metals and Currencies Shine 
South Korea Exports Hit Record High as Global Trade Momentum Builds 
Asian Currencies Trade Flat as Dollar Weakens in Thin New Year Trading 
Oil Prices Stabilize at Start of 2026 as OPEC+ Policy and Geopolitical Risks Shape Market Outlook 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
South Korean Won Slides Despite Government Efforts to Stabilize Currency Markets 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
U.S. Dollar Steadies Ahead of Fed Minutes as Markets Eye Policy Divisions 
U.S. Stock Futures Slip as Year-End Trading Turns Cautious 
China Imposes 55% Tariff on Beef Imports Above Quota to Protect Domestic Industry 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Lotte Corporation recently formed Lotte Biologics as its newest business unit to venture further into the bio business sector. As the new division starts to operate independently, the company assigned an executive to lead the new team.
According to The Korea Herald, Lotte chose a former Samsung Biologics executive, Lee Won Jik, to be Lotte Biologics’ chief executive officer. He was only given the role of CEO now, but he actually Lotte Corporation in August of last year. Prior to his move, Lee worked as the head of Samsung Biologics’ drug business unit.
Lotte Holdings announced last week that it had completed the registration of Lotte Biologics with a starting capital of KRW1 billion or around $790,000. Lotte Biologics is now in charge of the company’s new bio business, and key executives were already appointed as well. An official at Lotte Holdings said that its bio unit and its new CEO will be formally introduced at the Bio International Convention that will start on Monday, June 13, in San Diego, California.
It was last month when the Lotte Group revealed its plans to inject KRW2.5 trillion to expand its bio ventures over the next 10 years. Its biggest goal for this new investment is to become one of the world’s top 10 largest CDMOs or contract development and manufacturing organizations by the year 2030.
In any case, the company’s entrance into the bio-industry started with Lotte’s acquisition of Bristol Myers Squibb’s production plant in East Syracuse, New York. The company purchased it for $160 million, and this will be where Lotte is producing drugs for its CMO contracts.
Meanwhile, Lee Won Jik started working at Lotte Holdings last year as the company’s vice president of its new growth team and head of the ESG Management Innovation Office. He has more than two decades of experience in the global biologics and the pharmaceuticals business because aside from being a former executive at Samsung Biologics, he also worked at Bristol Myers Squibb and the U.S. Department of Health and Human Services.
As per the report, Lee Won Jik was not the only executive to be given a new role as Lotte also appointed Ha Jong Su, the company’s VP of global logistics SCM business unit, as the new inside director while Lee Hong Gi, Lotte’s healthcare unit chief, becomes the non-executive director.
